Inhibrx says OX40 agonist’s durability confirmed by ph. 2 win
Inhibrx says OX40 agonist’s durability confirmed by ph. 2 win
Inhibrx Biosciences
Protein-engineering and single-domain antibody platform company developing therapeutic candidates for oncology and rare diseases. Nasdaq: INBX.
Company Info
Upcoming Milestones & Key Dates
2026-Q4
Clinical
INBRX-105 OX40 agonist Phase 2 data update
2027-Q1
Clinical
INBRX-101 AATD Phase 2 readout
Clinical Development Pipeline
INBRX-101
Target: sdAb Fc-fusionINBRX-105
Target: OX40 agonist + Keytruda comboINBRX-106
Target: 4-1BB agonistRecent News
Inhibrx’s OX40 agonist add-on beats Keytruda alone in head and neck cancer
Inhibrx’s OX40 agonist add-on beats Keytruda alone in head and neck cancer
Leadership Team
Mark Lappe
Chief Executive Officer
Brendan Eckelman
Chief Scientific Officer
Kelly Deckwa
Chief Medical Officer